US 11,690,908 B2
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
John C. Williams, Monrovia, CA (US); Christine Brown, Pasadena, CA (US); and Don J. Diamond, Glendora, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US)
Filed by CITY OF HOPE, Duarte, CA (US)
Filed on Sep. 2, 2021, as Appl. No. 17/465,728.
Application 17/465,728 is a division of application No. 16/342,426, granted, now 11,116,834, previously published as PCT/US2017/057466, filed on Oct. 19, 2017.
Claims priority of provisional application 62/410,383, filed on Oct. 19, 2016.
Prior Publication US 2022/0062410 A1, Mar. 3, 2022
Int. Cl. A61K 35/17 (2015.01); A61K 39/12 (2006.01); A61K 48/00 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 39/245 (2006.01); A61P 35/00 (2006.01); C07K 14/03 (2006.01); C07K 16/18 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/03 (2013.01); C07K 14/7051 (2013.01); C07K 16/18 (2013.01); A61K 38/00 (2013.01); A61K 2039/5158 (2013.01)] 10 Claims
 
1. A method for forming a population of human T cells expressing a recombinant CAR protein and a T cell receptor specific for a CMV antigen, said method comprising: (1) administering a viral vector encoding: (a) a CMV pp65 protein and (b) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) to a CMV-seronegative human donor; (2) obtaining PBMCs from said human donor; (3) contacting said PBMCs with at least one CMV antigen; (3) allowing said contacted cells to produce a population of cells enriched for stimulated cells specific for CMV; (4) transducing at least a portion of said enriched population of cells with a vector expressing a recombinant CAR protein, thereby forming a population of human T cells expressing a T cell receptor specific for a CMV antigen and a recombinant CAR protein.